Diagnostic value of anti-GM1 ganglioside serology and validation of the INCAT-ELISA

J Neurol Sci. 2005 Dec 15;239(1):37-44. doi: 10.1016/j.jns.2005.07.009. Epub 2005 Sep 8.


The Inflammatory Neuropathy and Treatment (INCAT) group developed a standardized ELISA method for the detection of serum anti-GM1 antibodies. The diagnostic value of anti-GM1 antibodies determined by this method has not yet been established in large groups of patients. We assessed the reproducibility, sources of variation, optimal cut-off values and evaluated the diagnostic relevance of the INCAT-ELISA in various groups of patients and controls (N=1232). The coefficient of variance was 11.2% for IgM and 3.8% for IgG. High IgG titers were only found in Guillain-Barré syndrome (GBS) and other inflammatory polyneuropathies. High IgM titers were associated with GBS and multifocal motor neuropathy. Low IgM titers had no additional diagnostic value. The INCAT-ELISA is a reliable test with additional diagnostic value in specific clinical situations.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't
  • Validation Study

MeSH terms

  • Autoantibodies / analysis
  • Autoantibodies / blood*
  • Autoantibodies / immunology
  • Enzyme-Linked Immunosorbent Assay / methods*
  • Enzyme-Linked Immunosorbent Assay / trends
  • G(M1) Ganglioside / immunology*
  • Guillain-Barre Syndrome / blood*
  • Guillain-Barre Syndrome / diagnosis*
  • Guillain-Barre Syndrome / immunology
  • Humans
  • Immunoglobulin G / analysis
  • Immunoglobulin G / blood
  • Immunoglobulin M / analysis
  • Immunoglobulin M / blood
  • Peripheral Nerves / immunology*
  • Peripheral Nerves / pathology
  • Peripheral Nerves / physiopathology
  • Predictive Value of Tests
  • Reproducibility of Results


  • Autoantibodies
  • Immunoglobulin G
  • Immunoglobulin M
  • G(M1) Ganglioside